Pulmonx
Maria Breitenfeldt, PhD, serves as the Senior Director of Market Access Strategy at Pulmonx Corporation, focusing on payer relations, economic value, health economics and outcomes research (HEOR), reimbursement strategy, CMS policy, evidence planning, pricing strategy, and field team management since October 2021. Prior experience includes a role as Director of Global Health Economics & Market Access at Boston Scientific, where Maria developed reimbursement and health economic strategies for various cardiac therapies. Additional roles include Director of Global Healthcare Economics & Reimbursement at Cardiovascular Systems, Inc., and Senior Manager of Global Health Economics & Reimbursement at Medtronic, specializing in cardiac rhythm and heart failure products. Early career roles encompassed scientific writing and research management at R&D Systems and academic positions at the University of Minnesota and Carleton College. Maria holds a B.S. in Molecular Biophysics & Biochemistry from Yale University and a Ph.D. in Molecular Cell Developmental Biology from the University of Minnesota.
Previous companies
This person is not in any teams
This person is not in any offices
Pulmonx
2 followers
Pulmonx has developed the Zephyr Endobronchial Valve, a minimally invasive treatment for COPD/emphysema. The one-time procedure is done by bronchoscopy and requires no cutting or incisions. During the procedure, on average 4 tiny valves are placed in the airways to block off the diseased parts of the lung which allows trapped air to escape until the lobe is reduced. Reducing hyperinflation allows the healthier parts of the lungs to expand and take in more air. This results in patients being able to breathe easier and have less shortness of breath.1